The Advanced Mitochondrial Stack: Mito-Peptides + Cofactors

Key Takeaways

Across three cohorts totalling 27,527 people, men who carry a particular variant of mitochondrial DNA have a higher prevalence of type 2 diabetes. The variant swaps a single amino acid in MOTS-c and makes the peptide less active. In one of those cohorts the excess risk showed up in only one group: men in the lowest third of physical activity. In active men the weaker peptide made no detectable difference.

That is the most instructive finding in the whole mitochondrial-peptide literature, and it is an instruction about order. Physical activity appears to cover for a deficient peptide. Nothing shows that a peptide covers for deficient activity.

So this stack is built upside down compared with what a peptide vendor would sell you. The training goes first. The supplements with human trials go second. MOTS-c goes last, labelled as an experiment, with a test built in to tell you whether it did anything. Humanin gets a reading list instead of a dose. And SLU-PP-332 is left out.

The Sentence That Comes First

This stack is graded D, because its named ingredient has no human trial. Layers 0 and 1 on their own are a solid B. If you stop after Layer 1 you have a defensible, evidence-based mitochondrial routine. Layer 2 is where the evidence ends and the experiment begins, and you should cross that line knowingly or not at all.

Do not start Layer 2 if you have or have had cancer, if you take insulin or a sulfonylurea, if you are pregnant, or if you compete in a tested sport.

The Layer Map

The dosing table and safety rules live on the Mito-Peptide Advanced protocol page. This article is the reasoning.

Layer 0 — The Signal You Already Own

Acute high-intensity exercise increases both humanin and MOTS-c in human skeletal muscle and plasma. Exercise induces endogenous MOTS-c expression in human muscle and in circulation. This is the only route to higher mitochondrial-peptide levels that has been demonstrated in people.

The plan: two to three interval sessions a week — hard efforts of one to four minutes with equal recovery — on top of two or three easier aerobic sessions. If you are not currently training, spend the first two weeks on the aerobic sessions alone.

Two honest limits. Whether training raises your resting peptide levels is conflicting across studies. And a 2026 study measuring blood entering and leaving an exercising human leg found no difference in MOTS-c — so working muscle may not be the source of what appears in the blood. You do not need either question settled to train: the outcome evidence for exercise does not depend on which peptide carries the message.

Layer 1 — Cofactors That Have Met a Placebo

CoQ10, 200 mg/day with a fat-containing meal. CoQ10 carries electrons between complexes of the respiratory chain. The reason it is in this stack is not the mechanism but the trials: a meta-analysis of 13 randomised controlled trials in 1,126 participants found a statistically significant reduction in fatigue scores versus placebo (Hedges' g −0.398). The effect was consistent in healthy and unwell participants, grew with daily dose and with treatment duration, and came with a single gastrointestinal adverse event among 602 people treated.

For a sense of the ceiling: in the two-year Q-SYMBIO trial in chronic heart failure, 100 mg three times daily cut major adverse cardiovascular events from 26% to 15% and all-cause mortality from 18% to 10%. That is a sick population and a different question, but it is the kind of outcome data nothing else in this stack has. If you take a statin, the case for this layer is stronger still — see CoQ10 and statin mitochondrial protection.

PQQ, 20 mg/day — optional. PQQ is sold as a mitochondrial biogenesis supplement, and the best trial half-supports that. Twenty-three untrained men did six weeks of supervised endurance training on PQQ or placebo. PGC-1α protein rose significantly more on PQQ. VO2peak and exercise duration improved in both groups with no difference between them, and body composition did not differ.

So PQQ moved a marker of the process without moving the result of the process over six weeks. That is a C. It may matter over longer horizons; nobody has shown it. Keep it if you already take it, skip it if cost matters.

The Week-4 Test — Why It Exists

Before any peptide, repeat your baseline functional test at week 4: a VO2max estimate or a fixed time trial you can reproduce exactly.

This is the piece most self-experiments omit, and without it the experiment cannot be read. You will get fitter in the first four weeks from training alone. If you start a peptide on day one, every gain is attributed to the vial. The week-4 number is your control: it captures what Layers 0 and 1 did, so that whatever happens in weeks 5–10 can be compared against a trajectory rather than against your untrained self.

It is still an n-of-1 with no blinding. It is simply the least bad design available to one person.

Layer 2 — MOTS-c, as an Experiment

MOTS-c activates AMPK by inhibiting the folate cycle, targets skeletal muscle, and in mice prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity. The 2026 work adds that it improves muscle mitochondrial efficiency through PGC-1α and AMPK without increasing respiratory protein content — it makes existing mitochondria work better.

Now the other column. There is no published trial of MOTS-c administration in humans: no pharmacokinetics, no dose-finding, no safety data. The dose on the protocol page is a community convention recorded on our MOTS-c profile. Vials come from an unregulated market.

If you run it:

• Weeks 5–10 only. Six weeks, on training days, then stop.
• Check fasting glucose weekly. It is an AMPK activator; the effect adds to metformin or berberine.
• Change nothing else. Same training, same cofactors, same sleep. Otherwise the week-10 test is uninterpretable.
• Buy only with a batch certificate of analysis from an independent laboratory, and treat even that as partial assurance.

If you skip it: continue Layers 0 and 1 to week 10 and test anyway. You will have a clean record of what training plus CoQ10 does for you, which is worth having.

Research Tier — Humanin Without a Dose

Humanin is the oldest and in some ways the most interesting member of the family. It binds Bax and blocks apoptosis. Its circulating level falls with age and is markedly higher in the children of centenarians. Its analogue improved metabolic healthspan markers in middle-aged mice.

It has never been administered to humans in a published study. There is therefore no dose to give you, and inventing one from rodent data for a peptide whose mechanism is suppressing cell death would not be responsible. Humanin is in this stack as something to read about — the background is in Humanin and MOTS-c: Mitochondrial-Derived Peptides Explained.

What This Stack Deliberately Excludes

SLU-PP-332. A small-molecule ERR agonist with impressive mouse data and no human study. Its developers reported in 2026 that it lacks oral bioavailability. The same paper found that a related compound added to exercise training raised exercise-responsive gene expression further than either alone. Full reading in the research update.

SS-31 and NMN. Not because they are without merit, but because they belong to a different strategy — repairing the inner membrane and restoring NAD+. That route is The Ultimate Mitochondrial Matrix, and the logic of its ordering is in why SS-31 must precede MOTS-c. Choose one route. Running both makes nothing attributable.

Stacking two "exercise mimetics." No combination of MOTS-c with any ERR or AMPK agonist has been studied in any species.

The Ten-Week Schedule

Exit Criteria — Decide These at Week 0

• Week 10 no better than week 4 on the time trial → the experimental layer added nothing measurable. Do not repeat it.
• Any hypoglycaemic symptom or a fasting reading below 70 mg/dL (3.9 mmol/L) → stop MOTS-c that day.
• Fatigue score unchanged at week 10 despite adherence → this is not a mitochondrial-supplement problem. See a clinician about thyroid function, iron, sleep apnoea and mood.
• Any new lump, unexplained weight loss or persistent symptom → stop the peptide layer and get assessed. This is caution, not a known risk; it is the caution a class with no human safety data deserves.

Frequently Asked Questions

Why is a stack named after peptides mostly about exercise and CoQ10? Because that is where the human evidence is. Naming a stack after its most exciting ingredient is marketing; ordering it by evidence is the point of this site.

Can I run MOTS-c without the exercise layer? You can, but the genetic data suggest activity is what matters when the peptide signal is weak, and the mouse work shows exercise and MOTS-c act through partly distinct pathways. A peptide instead of training is the least-supported version of this stack.

Is this the same as the Mitochondrial Matrix protocol? No. That protocol leads with SS-31 and includes NMN; it is built around repair. This one is built around signalling and leads with training.

Why six weeks for MOTS-c? It is long enough to see a change against the week-4 baseline and short enough to limit exposure to a compound with no human safety data. It is a judgment, not a trial-derived duration.

Should I add humanin if I can source it? No. There is no human dose, no human safety data, and a mechanism that makes the cancer question non-trivial.

I am a competitive athlete. What can I use? Layers 0 and 1. AMPK activators and unapproved substances are prohibited, and detection methods for the newer compounds are being published.

Related Research

• The Mito-Peptide Advanced Protocol
• Humanin and MOTS-c: Mitochondrial-Derived Peptides Explained
• SLU-PP-332: The Exercise Mimetic Research Update
• MOTS-c: Exercise in a Vial
• Urolithin A + SS-31: The Mitochondrial Synergy Stack
• Coenzyme Q10